However, in our experiments we observed the immigration of immune cells into lymphoid vessels for the first time in vivo and also recorded and analyzed the transport of immune cells within lymphatic vessels. As these intravascular dynamics are extremely unlikely to be based on active cellular migration, the data implicates a passive transport via the lymph flow. Only limited data is available on lymph flow velocities in mice. Measurements range from 84 mm–81 mm/min, partly much faster than the velocities measured in our experiments. Nevertheless, the data available is based on studies of the lymphatic vessel system of tail and limb. To our knowledge no studies on lymph flow velocities in the vascularized cornea of mice have been conducted so far and velocities in the corneal stroma that consists of Rapamycin densely packed collagen fibrils might differ significantly from lymph flow velocities in connective tissues of other regions. Together with previous findings that lymphoid vessels in the model of suture induced corneal inflammation increase the risk of immunological transplant rejection following corneal transplantation, the demonstrated migration and intravascular transport of immune cells and the continuous staining pattern proves the functionality of these newly formed lymphatic vessels and their ability of draining foreign matter such as injected dyes or even antigen. Based on the setup and the data presented future experiments are planned to target two important issues: 1. How do immunosuppression and anti-angiogenesis influence cellular and vascular dynamics in connection to the level of inflammation2. The development of a setup that allows detecting and analyzing lymphatics and cellular dynamics without the necessity of manipulation such as dye injection as a requirement for studies in humans. Overall, this method paves the way for new intravital analyses of interactions of the immune system and lymphatic vessels as well as tumor cells and lymphatic vessels which has been of major scientific relevance in the last years. Ovarian cancer is the fifth leading cause of death from cancer in women, and the second most deadly gynecologic malignancy in the United States. Epithelial ovarian cancer accounts for about 3% of total cancer cases in women. National Cancer Institute estimated that in 2010, 21,880 women would be diagnosed and 13,850 women would die of cancer of the ovary. Ovarian cancer is a group of heterogeneous diseases and consists of different histological types, which can be readily differentiated by histological evaluation. Current clinical guidelines set forth by World Health Organization distinguish eight histological tumor subtypes: papillary serous carcinoma, endometrioid carcinoma, mucinous carcinoma, clear cell carcinoma, transitional cell carcinoma, squamous cell, mixed epithelial, and undifferentiated, with serous carcinoma displaying the most malignant phenotype. Genome-wide global gene analysis further defines distinct expression profiles of different types of ovarian cancer. Different histological types of ovarian cancer seem to be regulated by different pathogenic pathways. Most EMC and PSC present moderate to high levels of ER and AR expression.